CSIMarket
 
Iridex Corp  (NASDAQ: IRIX)
 

Iridex's Customers Performance

IRIX



 
IRIX's Source of Revenues During the corresponding time, Iridex Corp saw a revenue deteriorated by -0.91 % year on year, sequentially revenue grew by 7.03 %. While revenue at the Iridex Corp's corporate clients

List of IRIX Customers




for the same period Iridex Corp revnue deteriorated by -0.91 % year on year, sequentially revenue grew by 7.03 %.

List of IRIX Customers

Iridex's Business Units
Cyclo G Six    60.19 % of total Revenue
Retina    97.98 % of total Revenue
Cyclo G6    35.73 % of total Revenue
Service Contract Revenues Distribution Rights    2.2 % of total Revenue
US    87.52 % of total Revenue
Europe Middle East and Africa    54.07 % of total Revenue
Asia Pacific    43.36 % of total Revenue
Americas excluding the U S    8.95 % of total Revenue






Iridex's Comment on Sales, Marketing and Customers



The company operates in the global ophthalmology market, focusing on glaucoma and retinal disease. It targets glaucoma patients, estimated at 80 to 100 million worldwide, and patients with retinal disorders such as diabetic retinopathy, which affects a portion of the 463 million people with diabetes globally as of 2019. The company develops alternative treatments for these conditions to address unmet medical needs.


  News about Iridex Corp Contracts

Revolutionizing Glaucoma Treatment: The First Enrolment in Iridex-Imperial College Study

Iridex Corporation, situated in Mountain View, California, and Imperial College Healthcare NHS Trust in London, have announced their first patient enrolment in a collaborative medical research study. The study is set to explore the efficacy of treating glaucoma with MicroPulse Transscleral Laser Therapy (TLT) utilizing Iridex’s Cyclo G6 Laser and the MicroPulse P3 Delivery Device.In a world where glaucoma impacts an estimated 76 million individuals, fresh investigative approaches to the disease are not just welcomed but mandated. Recognized as the leading cause of irreversible blindness worldwide, glaucoma treatment is about to enter a new phase of study and inspection, thanks to this groundbreaking partne...




Iridex’s Comment on Sales, Marketing and Customers


The company operates in the global ophthalmology market, focusing on glaucoma and retinal disease. It targets glaucoma patients, estimated at 80 to 100 million worldwide, and patients with retinal disorders such as diabetic retinopathy, which affects a portion of the 463 million people with diabetes globally as of 2019. The company develops alternative treatments for these conditions to address unmet medical needs.








IRIX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Iridex Corp 12.19 49.19 -7.75 93
SUBTOTAL 0.00 0.00 0.00 -

Sources: Iridex Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Iridex Corp’s corporate clients.
For your research, we’ve provided 9 tables on Iridex Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.